With late-stage da­ta in on the CGRP mi­graine drug erenum­ab, No­var­tis and Am­gen re­work com­mer­cial­iza­tion pact

Five months af­ter Am­gen and No­var­tis out­lined their sec­ond batch of pos­i­tive Phase III da­ta for their CGRP mi­graine drug erenum­ab, the two gi­ants have re­worked their com­mer­cial part­ner­ship to give No­var­tis a piece of the US mar­ket — for a price.

Un­der their orig­i­nal deal Am­gen was left in charge of the US, but now No­var­tis has agreed to cov­er part of the com­mer­cial­iza­tion costs in ex­change for a slice of the rev­enue in the all-im­por­tant mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER